Alaska Medication Assistance Treatment (MAT) Expansion Capacity Project will address its opioid epidemic by using the most effective and FDA approved medications alongside evidence-based practices of Dual Recovery Therapy, Critical Time Intervention case management, peer support, vocational support, Trauma Informed Care, relapse prevention, motivational interviewing, cognitive-behavioral therapy among many others. The two identified communities receiving this award will be Anchorage and Juneau for not only their high Opioid Use Dependence prevalence rates but also the complete lack of MAT services in the entire Southeastern part of the state (where Juneau is located). This project expects to increase unduplicated individuals in Anchorage by approximately 60 for the first year of the project and 130-150 unduplicated individuals in years two and three. Unduplicated individuals in Juneau will be increased by approximately 45 for the first year of the project and 75-100 unduplicated individuals in years two and three. This increases Alaska's overall MAT capacity by 250 individuals. During 2009-2015, 774 drug overdose deaths were entered into the Alaska mortality database. Overall, 512 (66 percent) decedents had a prescription drug noted as the primary or a contributing cause of death. Of the 311 illicit drug overdose deaths that were recorded in the database, 128 (41 percent) noted heroin as either the primary or a contributing cause of death. Currently, Alaska only has a MAT capacity of 215 individuals in the nonprofit agency and 200 individuals in the one for profit. With upwards of 1,700 individuals with and Opioid Dependence or Abuse Disorder diagnosis seeking treatment, this leaves over 75 percent of known individuals going without MAT.